Insider Selling: Tempus AI (NASDAQ:TEM) EVP Sells 8,703 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin sold 8,703 shares of the business’s stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total transaction of $383,541.21. Following the completion of the sale, the executive vice president directly owned 128,215 shares of the company’s stock, valued at $5,650,435.05. This represents a 6.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Andrew Polovin also recently made the following trade(s):

• On Friday, February 20th, Andrew Polovin sold 10,949 shares of Tempus AI stock. The shares were sold at an average price of $60.31, for a total transaction of $660,334.19.

Tempus AI Stock Performance

NASDAQ TEM traded up $0.61 during trading on Thursday, reaching $46.49. The company’s stock had a trading volume of 3,802,434 shares, compared to its average volume of 5,629,236. The company has a current ratio of 3.31, a quick ratio of 3.15 and a debt-to-equity ratio of 2.96. The firm has a market capitalization of $8.35 billion, a price-to-earnings ratio of -27.03 and a beta of 3.99. Tempus AI, Inc. has a 12 month low of $41.73 and a 12 month high of $104.32. The firm has a 50 day moving average price of $49.11 and a 200 day moving average price of $59.69.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The firm had revenue of $348.12 million for the quarter, compared to analyst estimates of $345.44 million. During the same quarter last year, the company earned ($0.24) EPS. The company’s revenue was up 36.1% on a year-over-year basis. As a group, equities analysts anticipate that Tempus AI, Inc. will post -1.35 EPS for the current fiscal year.

Institutional Trading of Tempus AI

Institutional investors and hedge funds have recently modified their holdings of the business. JPL Wealth Management LLC bought a new stake in shares of Tempus AI during the 3rd quarter valued at approximately $26,000. Los Angeles Capital Management LLC bought a new stake in shares of Tempus AI during the 4th quarter valued at approximately $27,000. Harvest Fund Management Co. Ltd bought a new stake in shares of Tempus AI during the 3rd quarter valued at approximately $38,000. Whittier Trust Co. grew its holdings in shares of Tempus AI by 190.0% during the 1st quarter. Whittier Trust Co. now owns 870 shares of the company’s stock valued at $41,000 after purchasing an additional 570 shares during the last quarter. Finally, Lodestone Wealth Management LLC bought a new stake in shares of Tempus AI during the 4th quarter valued at approximately $42,000. 24.22% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on TEM. Wall Street Zen lowered Tempus AI from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. HC Wainwright cut their price objective on shares of Tempus AI from $95.00 to $64.00 and set a “buy” rating for the company in a research report on Monday, May 11th. Mizuho assumed coverage on shares of Tempus AI in a research report on Thursday, February 19th. They set an “outperform” rating and a $100.00 price objective for the company. Stifel Nicolaus set a $60.00 price objective on shares of Tempus AI in a research report on Wednesday, February 25th. Finally, Jefferies Financial Group started coverage on shares of Tempus AI in a research note on Monday, April 13th. They issued an “underperform” rating and a $35.00 price objective on the stock. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $68.64.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.